LDS/Medical Tests/Inherited Insulin Resistance Syndromes (INSR) Genetic Testing

Inherited Insulin Resistance Syndromes (INSR) Genetic Testing

Insulin resistance is defined as "a state (of a cell, tissue or organism) in which a greater than normal amount of insulin is required to elicit a quantitatively normal response." Insulin resistance is an important mechanism in the pathogenesis of certain types of diabetes and diabetes-like conditions including obesity, non-insulin dependent diabetes mellitus (type II diabetes), metabolic syndrome, pregnancy, polycystic ovarian syndrome, endocrinopathies, various chronic inflammatory conditions and autoimmune diseases. Insulin resistance can be broadly classified as intrinsic defects of insulin receptor and secondary defects. Inherited mutations (constitutional defects) in the insulin receptor (INSR) gene are rare and have been described recently to be associated with Donohue syndrome, Rabson-Mendenhall syndrome and type A syndrome.

Insulin resistance syndromes, whether inherited or acquired, share some common clinical and laboratory findings. Clinical manifestations of insulin resistance include acanthosis nigricans (velvety hyperpigmentation of skin) and hyperandrogenism (hirsutism, oligomenorrhea and infertility in post-pubertal females). Laboratory findings include hyperinsulinemia and impaired glucose tolerance or frank diabetes mellitus.

Type A insulin resistance syndrome is characterized by severe inherited insulin resistance and acanthosis nigricans in the absence of autoantibodies to the insulin receptor. In females, type A syndrome manifests also with hyperandrogenism, virilism, and markedly elevated testosterone levels. Both autosomal recessive and dominant patterns of inheritance have been reported. Most type A syndrome patients survive up to middle age and beyond. Rabson-Mendenhall syndrome is an autosomal recessive disease and presents in childhood with severe intractable insulin resistance, growth abnormalities and multiple endocrinopathies. It carries a dismal prognosis due to complications of uncontrolled diabetes and most patients survive only to 5-15 years of age. Donohue syndrome is also inherited in autosomal recessive pattern and manifests very early in life with intrauterine and postnatal growth retardation, multiple dysmorphic features, severe insulin resistance, fasting hypoglycemia, hyperandrogenism and defects of the internal organs including lungs and kidneys. Prognosis is generally poor and most infants do not live more than a year.

The insulin receptor is a cell membrane protein composed of two extracellular α subunits and two transmembranous β subunits, both subunits being coded by a single INSR gene. Over 50 different mutations involving INSR have been reported in the literature. Donohue syndrome is associated with mutations involving the α subunit while Rabson-Mendenhall syndrome is associated with mutations involving the β subunit. Type A syndrome is multifactorial and the reported abnormalities include the β subunit, genes other than INSR, various epigenetic and environmental factors.

  • Diagnosis of inherited insulin resistance syndrome in patients with suggestive clinical features and laboratory findings
  • Diagnosis of Donohue syndrome
  • Diagnosis of Rabson-Mendenhall syndrome and type A syndrome
  • Disease management and therapeutic monitoring 

Interpretation of INSR sequencing requires clinicopathological correlation:

  • Mutations involving one allele of INSR with less severe clinical features predict carrier status for inherited insulin resistance syndrome.
  • Mutations involving one allele of INSR may also be compatible with autosomal dominant type A insulin resistance syndrome.
  • Mutations involving both the alleles with characteristic clinical features are consistent with inherited insulin resistance syndrome.
  • Novel biallelic mutations require clinicopathological correlation for definite classification of inherited insulin resistance syndromes or carrier status.
  • Mutations with uncertain clinical significance may also be detected. Clinical features and biochemical tests should guide further therapy in these individuals.

Negative for mutations analyzed (No mutation detected or INSR Wild type)

 

 

Conventional bidirectional sequencing, Next generation sequencing (NGS), Pyro-sequencing, PCR with ARMS.

Whole blood collected in lavender top tube (EDTA) or any anticoagulant collection devices, Buccal mucosal swab transported in appropriate medium.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Insulin levels, C-peptide, Insulin binding protein, Glucose, glucose tolerance test, insulin hourly, insulin antibody, ketone bodies, and comprehensive metabolic panel (see CMP for the content).
2-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login